[go: up one dir, main page]

WO2022009352A1 - Agent d'inactivation du coronavirus - Google Patents

Agent d'inactivation du coronavirus Download PDF

Info

Publication number
WO2022009352A1
WO2022009352A1 PCT/JP2020/026757 JP2020026757W WO2022009352A1 WO 2022009352 A1 WO2022009352 A1 WO 2022009352A1 JP 2020026757 W JP2020026757 W JP 2020026757W WO 2022009352 A1 WO2022009352 A1 WO 2022009352A1
Authority
WO
WIPO (PCT)
Prior art keywords
sars
polyoxyethylene alkyl
alkyl ether
ppm
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/026757
Other languages
English (en)
Japanese (ja)
Inventor
勢造 八城
悠記 石田
拓也 森本
和彦 片山
慧 芳賀
玲子 戸高
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Kitasato Institute
Original Assignee
Kao Corp
Kitasato Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp, Kitasato Institute filed Critical Kao Corp
Priority to PCT/JP2020/026757 priority Critical patent/WO2022009352A1/fr
Priority to JP2020540368A priority patent/JP6795720B1/ja
Priority to PCT/JP2020/027783 priority patent/WO2022009437A1/fr
Priority to JP2020187003A priority patent/JP6990285B1/ja
Publication of WO2022009352A1 publication Critical patent/WO2022009352A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/04—Oxygen or sulfur attached to an aliphatic side-chain of a carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to a SARS coronavirus-2 inactivating agent.
  • SARS coronavirus-2 (Severe acute respiratory syndrome 2,; SARS-CoV-2) belongs to the genus Beta coronavirus like SARS coronavirus (SARS-CoV) and MERS coronavirus (MERS-CoV), and acute respiration. It is a SARS-related coronavirus that causes organ disease (COVID-19). SARS-CoV-2 was first confirmed to occur near Wuhan City, Hubei City, China in 2019, and has since caused a pandemic of COVID-19.
  • ethanol and surface activity are used to prevent infection by inactivating the virus by cleaning and disinfecting hands, fingers, clothing, various instruments and parts that may have virus adherence.
  • disinfectants such as agents and hypochlorite water for SARS-CoV-2 has been evaluated.
  • Non-Patent Document 1 "We will announce effective surfactants for the new coronavirus.-Expanding options for disinfection methods for articles-", [online], [Search on July 8, 2nd year of Reiwa] , Internet ⁇ URL: https://www.nite.go.jp/information/osirase20200626.html>
  • the present invention relates to the following 1) to 3).
  • a SARS coronavirus-2 inactivating agent containing at least one polyoxyethylene alkyl ether selected from certain polyoxyethylene alkyl ethers as an active ingredient.
  • the concentration (X) of the linear alkylbenzene sulfonate is 20.0 ppm or more
  • a preventive agent for SARS coronavirus-2 infection containing at least one polyoxyethylene alkyl ether selected from certain polyoxyethylene alkyl ethers as an active ingredient.
  • the concentration (X) of the linear alkylbenzene sulfonate is 20.0 ppm or more, A preventive agent for SARS coronavirus-2 infection in which the concentration (Y) of the polyoxyethylene alkyl ether is 4.0 ppm or more and the following formula (1) is satisfied.
  • Y ⁇ 5000 ⁇ X- 1.5 (1)
  • a method for inactivating SARS coronavirus-2 which comprises contacting at least one polyoxyethylene alkyl ether selected from certain polyoxyethylene alkyl ethers with a subject of concern for contamination with SARS coronavirus-2.
  • the concentration (X) of the linear alkylbenzene sulfonate is 20.0 ppm or more
  • the present invention relates to providing a SARS-CoV-2 inactivating agent that exhibits an excellent SARS-CoV-2 inactivating effect.
  • the inactivating effect of SARS-CoV-2 was confirmed at a concentration of 0.1% or more for sodium linear alkylbenzene sulfonate and 0.2% or more for polyoxyethylene alkyl ether.
  • the present inventor has found that the SARS-CoV-2 inactivating effect is exhibited at a lower concentration by using a linear alkylbenzene sulfonate sodium and a polyoxyethylene alkyl ether in combination at a constant concentration relationship.
  • SARS-CoV-2 can be inactivated even when used at a low concentration of a surfactant, and the spread of SARS-CoV-2 infection can be prevented or reduced.
  • a linear alkylbenzene sulfonate a polyoxyethylene alkyl ether having 12 carbon atoms and 7 ethylene oxide addition moles of an alkyl group, and an alkyl group having 12 carbon atoms and 8 ethylene oxide addition moles.
  • At least one polyoxyethylene alkyl ether selected from the polyoxyethylene alkyl ethers is used in combination as an active ingredient for SARS coronavirus-2 inactivation.
  • polyoxyethylene alkyl ether having 12 carbon atoms and 7 ethylene oxide addition moles of the alkyl group and polyoxy having 12 carbon atoms and 8 ethylene oxide addition moles of the alkyl group may be simply referred to as "polyoxyethylene alkyl ethers”.
  • the linear alkylbenzene sulfonate is not particularly limited, but from the viewpoint of SARS-CoV-2 inactivation, the carbon number of the linear alkyl group is preferably 8 to 18, and more. It is preferably 9 to 16, and more preferably 9 to 15.
  • the counterion forming the salt of the linear alkylbenzene sulfonate include alkali metal, alkaline earth metal, ammonia, alkanolamine and the like. It is preferably an alkali metal, more preferably sodium.
  • the linear alkylbenzene sulfonate may be used alone or in combination of two or more.
  • the linear alkylbenzene sulfonate is available as a commercial product and may be purified to a high degree of purity or may have a distribution in the number of carbon atoms of the linear alkyl group. Further, it may be chemically synthesized by a conventional method.
  • the polyoxyethylene alkyl ether has a polyoxyethylene alkyl ether having 12 carbon atoms and 7 ethylene oxide mols, and an alkyl group having 12 carbon atoms and 8 ethylene oxide mols.
  • the polyoxyethylene alkyl ether is available as a commercially available product, and may be purified to a high degree of purity or may have a distribution in the number of moles of ethylene oxide added. Further, it may be chemically synthesized by a conventional method.
  • the concentration of linear alkylbenzene sulfonate (X (ppm)) and the concentration of polyoxyethylene alkyl ether (Y (ppm)) are as follows. 1) is satisfied. Y ⁇ 5000 ⁇ X- 1.5 (1)
  • X and Y satisfy the following formula (1a) and further, the following formula (1b) from the viewpoint of SARS-CoV-2 inactivation.
  • the concentration (X) of the linear alkylbenzene sulfonate is 20.0 ppm or more
  • the concentration (Y) of the polyoxyethylene alkyl ether is 4.0 ppm or more
  • the concentration (X) of the linear alkylbenzene sulfonate is 20.0 ppm or more, preferably 25.0 ppm or more, more preferably 50.0 ppm or more, and more preferably 50.0 ppm or more, from the viewpoint of SARS-CoV-2 inactivation. From the viewpoint of cost and damage to the inactivated target, it is 300 ppm or less, preferably 200 ppm or less, and more preferably 100 ppm or less.
  • the concentration (Y) of the polyoxyethylene alkyl ether is 4.0 ppm or more, preferably 10.0 ppm or more, more preferably 25 ppm or more, and more preferably 25 ppm or more, from the viewpoint of SARS-CoV-2 inactivation. From the viewpoint of cost and damage to the inactivated target, it is 300 ppm or less, preferably 200 ppm or less, and more preferably 100 ppm or less.
  • the quantification of the surfactant in the present specification shall be in accordance with the qualitative and quantification of the anionic surfactant and the nonionic surfactant in the JIS K 3362: 2008 household synthetic detergent test method.
  • SARS-CoV-2 is a SARS-related coronavirus that causes acute respiratory disease (COVID-19).
  • SARS-CoV-2 is a single-stranded plus-strand RNA virus with a viral genome of 29,903 bases.
  • the virus particles (virions) have a size of about 50 to 200 nm.
  • RNA proteins known as spike proteins, nucleoproteins, endogenous membrane proteins, and enveloped proteins, and RNA.
  • nucleocapsids bind to RNA to form nucleocapsids, and lipid-bound spike proteins, endogenous membrane proteins, and enveloped proteins surround them to form envelopes (A pneumonia outbreak associated with a new coronavirus of probable). bat origin. Nature. 2020 Mar; 579 (7798): 270-273., A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar; 579 (7798): 265-269.).
  • Peplomers are large transmembrane proteins of type I consisting of two subunits, S1 and S2, where S1 is primarily a receptor binding domain (RBD) that recognizes cell surface receptors and S2 is a membrane fusion. Contains the necessary elements.
  • ACE2 angiotensin converting enzyme 2
  • DPP4 dipeptidyl peptidase-4
  • APN aminopeptidase N
  • CEACAM cancer fetal antigen-related cell adhesion molecule 1
  • O- There is ac Sia O-acetylated sialic acid
  • SARS-CoV-2 Spike Glycoprotein Cell. Volume 181, Issue 2, 16 April 2020, Pages 281-292.e6).
  • the anti-SARS-CoV-2 verification test in the present specification is performed by a system in which SARS-CoV-2 treated with an inactivating agent to be evaluated is infected with Vero E6 / TMPRSS2 cells. Details will be described later.
  • the inactivating effect is defined as the case where about 10,000 viruses are almost completely inactivated (below the detection limit) in the verification test.
  • the linear alkylbenzene sulfonate and the polyoxyethylene alkyl ether having 12 carbon atoms and 7 ethylene oxide addition moles of the alkyl group and the poly having 12 carbon atoms and 8 ethylene oxide addition moles of the alkyl group Since the combination of at least one polyoxyethylene alkyl ether selected from oxyethylene alkyl ethers exhibits a SARS-CoV-2 inactivating effect, it can be a SARS-CoV-2 inactivating agent and can be a SARS-CoV-2 inactivating agent. Can be used for activation. It can also be used to produce the SARS-CoV-2 inactivating agent.
  • Non-therapeutic is a concept that does not include medical practice, that is, a concept that does not include a method of surgery, treatment or diagnosis of humans, more specifically, surgery on humans by a doctor or a person who has been instructed by a doctor. , A concept that does not include a method of performing treatment or diagnosis.
  • SARS-COV-2 infection refers to an acute respiratory disease (COVID-19) caused by infection with SARS-COV-2.
  • the symptoms are not specific and range from asymptomatic (asymptomatic) to severe pneumonia. Typical symptoms / signs include fever, dry cough, fatigue, sputum, shortness of breath, sore throat, headache, diarrhea, etc., but the present invention is not limited to such symptoms.
  • prevention means preventing, suppressing or delaying SARS-COV-2 infection in an individual, or reducing the risk of developing SARS-COV-2 infection.
  • “Improvement” means infection of SARS-COV-2 or improvement of symptoms, prevention or delay of worsening of symptoms, or reversal, prevention or delay of progression of symptoms, and is intended to include "treatment”.
  • the SARS-CoV-2 inactivating agent of the present invention may be in the form of using a linear alkylbenzene sulfonate and a polyoxyethylene alkyl ether, and depending on the mode of use, these and an appropriate solvent or preparation may be used. It may be in the form of a composition containing other components such as additives. The composition may be in an undiluted form or in a diluted form. The undiluted form is used for SARS-CoV-2 inactivation to be treated without being diluted.
  • the concentration after being diluted with the recommended dilution concentration is the above-mentioned active ingredient concentration at which the SARS-CoV-2 inactivating effect is exhibited by the linear alkylbenzene sulfonate and the polyoxyethylene alkyl ether. It is diluted with a suitable medium such as water and used for SARS-CoV-2 inactivation to be treated.
  • the SARS-CoV-2 inactivating agent is used for cleaning hands and fingers, foods such as vegetables and fish, hard surfaces of inanimate objects, fibers and textile products, etc., which may be contaminated with SARS-CoV-2.
  • Hard surfaces include floors, walls, windows, doors, food processing equipment, medical equipment, dressing rooms and toilets, bathrooms, washrooms, shower stands, kitchens, living rooms, etc. Various furniture such as bedrooms, home appliances, appliances, tools, etc. can be mentioned.
  • Examples of the material of the hard surface include plastic (including silicone resin and the like), metal, pottery, wood, glass, or a combination thereof.
  • Examples of textiles and textile products include clothing, towels, masks, sofas, cushions, bedding, curtains, shoes, bags and the like.
  • the SARS-CoV-2 inactivating agent of the present invention may be brought into contact with the treatment target.
  • the contact time is 10 seconds or more, preferably 1 minute or more, more preferably 10 minutes or more from the viewpoint of SARS-CoV-2 inactivation, and 24 hours or less, preferably 1 hour or less from the viewpoint of workload. More preferably, it is 30 minutes or less.
  • the means of contact is not particularly limited, and examples thereof include coating or spraying, dipping, washing, adding, and volatilizing.
  • the form of the product or the pharmaceutical product can be appropriately selected depending on the intended use, and may be, for example, liquid, gel-like, paste-like, or solid-like.
  • alkylbenzene sulfonic acid or a salt thereof and polyoxyethylene alkyl ether are applied or impregnated on a woven fabric or non-woven fabric of paper, natural fiber, recycled fiber (rayon, etc.) and / or synthetic fiber (polyester, polypropylene, polyester, etc.).
  • Can be in the form of Specific product and formulation forms include, for example, skin cleaners such as hand soaps, kitchen cleaners, laundry cleaners, softeners, household cleaners, toilet cleaners, bath cleaners, contact lens cleaners / preservatives.
  • the above-mentioned products and formulations can be prepared according to a conventional method by appropriately combining the above-mentioned active ingredient of the present invention or other ingredients other than the above-mentioned active ingredient within a range that does not impair the effect of the present invention.
  • Such other components include, for example, chelating agents, water-soluble solvents, oils, higher fatty acids, silicones, alkaline agents, pH regulators, water softeners, metal sequestering agents, dispersants, stabilizers, enzymes, fluorescent compounds. Examples thereof include whitening agents, bleaching agents, moisturizing agents, thickening agents, suspending agents, preservatives, antibacterial agents, defoaming agents, powder components, pigments, fluorescent dyes, fragrances, and other surfactants.
  • surfactants include linear alkylbenzene sulfonates, polyoxyethylene alkyl ethers with 12 carbon atoms and 7 ethylene oxide addition moles, and ethylene oxide addition moles with 12 alkyl groups.
  • Ionic surfactants anionic surfactants, cationic surfactants, amphoteric surfactants
  • examples thereof include activators and polymer surfactants.
  • the content of the active ingredient of the present invention in the SARS-CoV-2 inactivating agent of the present invention can be appropriately determined according to the form of the composition. Suitable contents in products and preparations assuming dilution are 1% by mass or more and 30% by mass or less for linear alkylbenzene sulfonate and 0.1% by mass or more and 20% by mass or less for polyoxyethylene alkyl ether. More preferably, the linear alkylbenzene sulfonate is 5% by mass or more and 15% by mass or less, and the polyoxyethylene alkyl ether is 0.5% by mass or more and 5% by mass or less.
  • Suitable contents in products and preparations that are not expected to be diluted are 12.5 ppm or more and 300 ppm or less for linear alkylbenzene sulfonate and 4 ppm or more and 300 ppm or less for polyoxyethylene alkyl ether, but more preferably linear alkylbenzene sulfonate.
  • the acid salt is 25 ppm or more and 200 ppm or less
  • the polyoxyethylene alkyl ether is 5 ppm or more and 200 ppm or less.
  • Example 1 [Anti-SARS-CoV-2 verification test] The outline of the anti-SARS-CoV-2 verification test is as follows. (material) SARS-CoV-2: JPN / TY / WK-521 Cell: Vero E6 / TMPRSS2 (JCRB1819) Medium: 500 mL DMEM (High Glucose) (Nacalai Tesque, 08459-64) 10mL G 418 Disulfate Aqueous Solution (Nacalai Tesque, 09380-44) 5mL Penicillin-Streptomycin (10,000 U / mL) (Gibco, 15140122) FBS: biosera, FB-1365 / 500, Lot10259 Deactivated 56 ° C, 30 minutes Addition to 5% medium during normal culture Addition to 2% medium during infection Trypsin: TrypLE® Select Enzyme (1X), no phenol red (Gibco, 12563011) RT-qPCR: SARS-CoV-2 Detection Kit
  • SARS-CoV-2 inactivation was judged by viral cytopathic effect and RT-qPCR. Microscopic observation using IX73 (Olympus) showed no viral cytopathic effect, or RT-qPCR of the culture supernatant. When the virus genome could not be detected, it was judged that SARS-CoV-2 was inactivated. In RT-qPCR, it was judged that the virus had propagated when the Ct (Threshold Cycle) value was less than 30.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention fournit un agent d'inactivation du ＳＡＲＳ－ＣｏＶ－２ qui présente d'excellents effets d'inactivation du ＳＡＲＳ－ＣｏＶ－２.　Plus précisément, l'invention concerne un agent d'inactivation du ＳＡＲＳ coronavirus-2 ayant pour principes actifs : un benzènesulfonate d'alkyle à chaîne droite ; et au moins une sorte de polyoxyéthylène alkyle éther choisie parmi un polyoxyéthylène alkyle éther de nombre de moles d'oxyde d'éthylène additionnées égal à 7 et de 12 atomes de carbone dans un groupe alkyle, et un polyoxyéthylène alkyle éther de nombre de moles d'oxyde d'éthylène additionnées égal à 8 et de 12 atomes de carbone dans un groupe alkyle. La concentration (X) en benzènesulfonate d'alkyle à chaîne droite est supérieure ou égale à ２０,０ｐｐｍ, et la concentration (Y) en polyoxyéthylène alkyle éther est supérieure ou égale à ４,０ｐｐｍ. Enfin, la formule (1) suivante est satisfaite.　Ｙ≧５０００×Ｘ－１,５　（１）
PCT/JP2020/026757 2020-07-08 2020-07-08 Agent d'inactivation du coronavirus Ceased WO2022009352A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/JP2020/026757 WO2022009352A1 (fr) 2020-07-08 2020-07-08 Agent d'inactivation du coronavirus
JP2020540368A JP6795720B1 (ja) 2020-07-08 2020-07-17 コロナウイルス不活化剤
PCT/JP2020/027783 WO2022009437A1 (fr) 2020-07-08 2020-07-17 Agent d'inactivation du coronavirus
JP2020187003A JP6990285B1 (ja) 2020-07-08 2020-11-10 コロナウイルス不活化剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2020/026757 WO2022009352A1 (fr) 2020-07-08 2020-07-08 Agent d'inactivation du coronavirus

Publications (1)

Publication Number Publication Date
WO2022009352A1 true WO2022009352A1 (fr) 2022-01-13

Family

ID=79552480

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2020/026757 Ceased WO2022009352A1 (fr) 2020-07-08 2020-07-08 Agent d'inactivation du coronavirus
PCT/JP2020/027783 Ceased WO2022009437A1 (fr) 2020-07-08 2020-07-17 Agent d'inactivation du coronavirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/027783 Ceased WO2022009437A1 (fr) 2020-07-08 2020-07-17 Agent d'inactivation du coronavirus

Country Status (1)

Country Link
WO (2) WO2022009352A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010168372A (ja) * 2008-12-25 2010-08-05 Kao Corp バイオフィルム生成抑制方法
WO2019194058A1 (fr) * 2018-04-02 2019-10-10 株式会社大阪製薬 Agent éliminateur des poux
IN202041019785A (fr) * 2020-05-11 2020-06-05
GB2580006A (en) * 2020-04-29 2020-07-08 Anthony Holmes Michael Bubbles for air decontamination

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010168372A (ja) * 2008-12-25 2010-08-05 Kao Corp バイオフィルム生成抑制方法
WO2019194058A1 (fr) * 2018-04-02 2019-10-10 株式会社大阪製薬 Agent éliminateur des poux
GB2580006A (en) * 2020-04-29 2020-07-08 Anthony Holmes Michael Bubbles for air decontamination
IN202041019785A (fr) * 2020-05-11 2020-06-05

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Final Report on Efficacy Assessment of Disinfecting Substances Alternative to Alcohol for Use Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) ", NATIONAL INSTITUTE OF TECHNOLOGY AND EVALUATION (NITE), 26 June 2020 (2020-06-26), XP055897801, Retrieved from the Internet <URL:https://www.nite.go.jp/data/000115863.pdf> [retrieved on 20220304] *
JAHROMI REZA; MOGHARAB VAHID; JAHROMI HOSSEIN; AVAZPOUR AREZOO: "Synergistic effects of anionic surfactants on coronavirus (SARS-CoV-2) virucidal efficiency of sanitizing fluids to fight COVID-19", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 145, 26 August 2020 (2020-08-26), GB , XP086284427, ISSN: 0278-6915, DOI: 10.1016/j.fct.2020.111702 *
PRAMOD, K. ET AL.: "Surfactant-based prophylaxis and therapy against COVID-19: A possibility", MEDICAL HYPOTHESES, vol. 143, no. 110081, 7 July 2020 (2020-07-07), XP086271908, DOI: 10.1016/j, mehy.2020.110081 *

Also Published As

Publication number Publication date
WO2022009437A1 (fr) 2022-01-13

Similar Documents

Publication Publication Date Title
WO2013012007A1 (fr) Composition d&#39;agent anti-virus
JP6990285B1 (ja) コロナウイルス不活化剤
JP2019182936A (ja) 液体洗浄剤
JP6444104B2 (ja) 洗濯用液体殺菌洗浄剤組成物およびそれを用いた繊維品の非エンベロープウイルスの不活化方法
WO2022085710A1 (fr) Agent d&#39;inactivation de coronavirus
JP7421902B2 (ja) ウイルス不活性化剤組成物
JP2019210266A (ja) 殺菌・ウイルス不活化剤及び殺菌・ウイルス不活化方法
WO2022009352A1 (fr) Agent d&#39;inactivation du coronavirus
JP7421904B2 (ja) ウイルス不活性化剤組成物
JP2022026765A (ja) ウイルス不活性化剤組成物
WO2022244531A1 (fr) Détergent neutre anti-virus enveloppé, composition désinfectante et procédé d&#39;inactivation de virus enveloppés
JP7421903B2 (ja) ウイルス不活性化剤組成物
JP2022026762A (ja) ウイルス不活性化剤組成物
JP2019151734A (ja) 硬質表面用殺黴洗浄剤組成物
JP7340290B2 (ja) 抗エンベロープウイルス中性洗浄剤、消毒剤組成物、及びエンベロープウイルスの不活性化方法
JP2022029409A (ja) 抗ウイルス組成物
JP2022056115A (ja) 洗浄剤組成物、スプレーボトル型洗浄剤、ウェットワイパー及び物品表面の洗浄方法
JP7378181B1 (ja) 洗浄剤組成物
JP2024044307A (ja) 液体ウイルス不活化組成物
JP7534729B2 (ja) Ｓａｒｓコロナウイルス２不活性化剤
WO2023145619A1 (fr) Composition d&#39;inactivation de virus non enveloppé
JP2023111855A (ja) 非エンベロープウイルス不活化組成物
JP2019151735A (ja) 硬質表面用殺黴洗浄剤組成物
EP4473834A1 (fr) Procédé d&#39;inactivation de virus ou de bactérie
JP2016141673A (ja) ウイルス不活化のための液体組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20944533

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20944533

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP